AIM AND BACKGROUND: Intestinal alkalization could prevent irinotecan associated diarrhea modulating some chemical equilibria between irinotecan metabolites. The aim of this study was to evaluate the efficacy of this procedure in advanced gastrointestinal cancer patients (GICP). MATERIALS AND METHOD: In this prospective study advanced GICP, receiving irinotecan based chemotherapy regimens, were well trained to add sodium bicarbonate to the water intake in order to accomplish intestinal alkalization. RESULTS: A total of twenty four advanced GICP were enrolled. Grade III-IV diarrhea has been observed in four patients (16%), some of whom had several risk factors for diarrhea. Only one out of seventeen colorectal cancer patients, receiving the irinotecan combination as first line therapy, had grade III-IV diarrhea. No side effects of the procedure have been appreciated. CONCLUSIONS: Intestinal alkalization may be effective as a preventive treatment for irinotecan associated diarrhea in chemotherapy regimens used in GICP. This procedure deserves further investigation.
AIM AND BACKGROUND: Intestinal alkalization could prevent irinotecan associated diarrhea modulating some chemical equilibria between irinotecan metabolites. The aim of this study was to evaluate the efficacy of this procedure in advanced gastrointestinal cancerpatients (GICP). MATERIALS AND METHOD: In this prospective study advanced GICP, receiving irinotecan based chemotherapy regimens, were well trained to add sodium bicarbonate to the water intake in order to accomplish intestinal alkalization. RESULTS: A total of twenty four advanced GICP were enrolled. Grade III-IV diarrhea has been observed in four patients (16%), some of whom had several risk factors for diarrhea. Only one out of seventeen colorectal cancerpatients, receiving the irinotecan combination as first line therapy, had grade III-IV diarrhea. No side effects of the procedure have been appreciated. CONCLUSIONS: Intestinal alkalization may be effective as a preventive treatment for irinotecan associated diarrhea in chemotherapy regimens used in GICP. This procedure deserves further investigation.
Authors: Ron H J Mathijssen; Jaap Verweij; Maja J A de Jonge; Kees Nooter; Gerrit Stoter; Alex Sparreboom Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: M L Rothenberg; J G Kuhn; H A Burris; J Nelson; J R Eckardt; M Tristan-Morales; S G Hilsenbeck; G R Weiss; L S Smith; G I Rodriguez Journal: J Clin Oncol Date: 1993-11 Impact factor: 44.544
Authors: D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait Journal: Lancet Date: 1998-10-31 Impact factor: 79.321
Authors: P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques Journal: Lancet Date: 1998-10-31 Impact factor: 79.321
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Randy M Wadkins; Janice L Hyatt; Kyoung Jin P Yoon; Christopher L Morton; Richard E Lee; Komath Damodaran; Paul Beroza; Mary K Danks; Philip M Potter Journal: Mol Pharmacol Date: 2004-06 Impact factor: 4.436
Authors: Floris A de Jong; Ron H J Mathijssen; Rujia Xie; Jaap Verweij; Alex Sparreboom Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Femke M de Man; Andrew K L Goey; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins Journal: Clin Pharmacokinet Date: 2018-10 Impact factor: 6.447
Authors: V M Coyle; D Lungulescu; C Toganel; A Niculescu; S Pop; T Ciuleanu; C Cebotaru; J Devane; M Martin; R H Wilson Journal: Br J Cancer Date: 2013-03-05 Impact factor: 7.640